Interestingly, this common target gene set exhibits significant higher expression across all fusion protein expressing AML subtypes as compared to normal CD34+ cells (Figure 3B), but similar to CMP and GMP progenitor populations, suggesting these represent the differentiation stage in which the AMLs are blocked. This evidence concerns the gene CD34 and acute myeloid leukemia.